Ventas (VTR) Stock Forecast & Price Target

Ventas is attractive because its nearly 1,400-property healthcare portfolio is diversified across senior housing, medical office, hospitals, life science, and skilled nursing, with about 100 properties in Canada and the United Kingdom and mortgage and loan assets adding another layer of income. Strong SHOP operating momentum is the clearest fundamental driver, with same-store NOI growth of 15.4% in 1Q26 and 15.9% YTD, while occupancy gains and a 97% occupancy level in the LGM portfolio support durable cash flow expansion. The outlook is further reinforced by a healthier balance sheet, with net debt to EBITDA down to 5.0x in 1Q26, and by an active investment pipeline that could support roughly $3.0 billion to $4.5 billion of annual acquisitions and continued AFFO growth.

Ventas is facing a less attractive risk-reward profile because its growth is increasingly reliant on continued capital deployment into a more competitive acquisition market, even as management raised 2026 investment guidance to $4.5 billion after completing $3.2 billion YTD. The outlook is further pressured by declining cap rates, which management still finds in the mid-6.0% range but are expected to drift to 6.25% in 2027 and 6.00% in 2028, potentially squeezing future accretion. In addition, the stock remains exposed to regulatory and funding uncertainty, including potential cuts to government-funded programs and NIH budget reductions that could affect its 8% R&I/Wexford exposure.